DONQ52 for Celiac Disease With Ongoing Symptoms Despite a Gluten-Free Diet
Tests DONQ52 against placebo in adults with celiac disease on a gluten-free diet.
Key facts
- Who runs it
- Chugai Pharmaceutical
- Where
- Auckland, Christchurch, Dunedin, Hamilton, Pukekohe, Upper Hutt, and Wellington, New ZealandSee the 7 sitesAlso in 2 other countries, 67 sites
- Trial code
- Registry title
- Study of DONQ52 in Active Celiac Disease
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 92 people, planned
- Started
- 16 Dec 2025
- Expected to end
- 15 Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Placebo DONQ52
- Simulated Inadvertent Gluten Exposure (SIGE) capsule
- DONQ52
- Record updated
- 14 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with celiac disease who still have gut damage and symptoms despite trying a gluten-free diet.
- Age
- 18 Years to 75 Years
- Sex
- All sexes can join.
- Disease stage
- Active celiac disease diagnosed by a doctor and written in medical records. Ongoing damage to the lining of the small intestine (Vh:Cd of 2.5 or less). At least 2 gluten-related symptom events (diarrhea, abdominal pain, bloating, nausea, tiredness) within a month before screening. Body mass index (BMI) of 18 to 40 (kg/m2).
- Earlier treatment
- Must have tried a gluten-free diet for at least 12 months before screening. Must be willing to eat study gluten products and have 2 endoscopies with small-bowel biopsies.
- Biomarker or test result
- Blood test showing the HLA DQ2.5 genotype (HLA-DQA1*05 and HLA-DQB1*02), one or two copies. People with HLA-DQ8 cannot join.
Main reasons for not taking part
- Refractory celiac disease (celiac disease that does not respond to diet), diagnosed or suspected
- Cancer within 5 years, or T cell or B cell lymphoma ever
- IgE allergy to wheat, barley, rye or study product ingredients, or severe allergy to biological medicines
- Other chronic active gut disease, or current Helicobacter pylori infection
- Positive test for HIV, hepatitis B, hepatitis C (unless HCV RNA negative) or active tuberculosis
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Body mass index (BMI) of 18 to 40 (kg/m2) at screening
- Willingness to ingest a gluten-free product and Simulated Inadvertent Gluten Exposure (SIGE) products as per the study protocol
- History of medically diagnosed, and adequately documented (i.e., included in the participant's medical records), CeD
- Attempting a GFD for at least 12 months prior to the screening visit; The participants should be instructed not to alter dietary habits including a GFD during the study period
- Valid results from central testing of blood documenting a positive result for the HLA DQ2.5 genotype (HLA-DQA1*05 and HLA-DQB1*02) (homozygous or heterozygous)
- Experienced at least 2 gluten-related symptom events (i.e., 2 different gluten-related symptoms which are diarrhea, abdominal pain, bloating, nausea, tiredness or 1 gluten-related symptom occurred twice) within a month before the screening
- Willingness to undergo 2 on-study upper gastrointestinal endoscopies with duodenal biopsies
- Presence of ongoing duodenal mucosal damage defined as Vh:Cd of 2.5 or less
Who cannot take part
- Participants with documented history (i.e., included in the participant's medical records) of medically diagnosed Refractory Celiac Disease (RCD) or suspected RCD by the investigator
- History of IgE-mediated reactions to wheat, barley, rye, or other ingredients in gluten-free and SIGE products used in this study (i.e., methylcellulose, and gelatin)
- History of cancer, including hematological malignancy and solid tumors, within 5 years prior to the screening visit, or history of T cell lymphoma or B cell lymphoma ever
- History of hypersensitivity reactions including anaphylaxis to a biological medical product or any of the excipients
- Any other chronic, active gastrointestinal disease (e.g., inflammatory bowel disease, microscopic colitis, eosinophilic esophagitis, peptic ulcer, gastroesophageal reflux disease, functional dyspepsia, or irritable bowel syndrome) that might in the investigator's opinion, interfere with the assessment of GI symptoms or small intestinal histology
- Helicobacter pylori tests that indicate current infection
- Positive either human immunodeficiency virus (HIV) antigen or antibody test at screening
- Positive hepatitis B surface antigen (HBsAg) test or total hepatitis B core (HBc) antibody test at screening
- Positive hepatitis C virus (HCV) antibody test at screening, except in participants who have negative results for HCV ribonucleic acid (RNA) test at screening
- Positive for QuantiFERON-TB Gold test at screening that indicates active tuberculosis (TB) at screening
- Participants who carry the HLA-DQ8 (HLA-DQA1*03 and DQB1*0302) genotype (homozygous or heterozygous)
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial is currently available in New Zealand.
Also in 2 other countries, 67 sites
- Pacific Clinical Research Network - AucklandAuckland, New ZealandTaking people
- CGM Research TrustChristchurch, New ZealandTaking people
- Momentum Clinical Research, DunedinDunedin, New ZealandTaking people
- Pacific Clinical Research Network Hamilton, WaikatoHamilton, New ZealandTaking people
- Momentum Clinical Research - PukekohePukekohe, New ZealandTaking people
- PCRN WellingtonUpper Hutt, New ZealandTaking people
- P3 Research Limited (Wellington)Wellington, New ZealandTaking people
About the trial
What the trial wants to find out
The main aim is to see how DONQ52 works to improve small intestinal damage and reduce celiac-related symptoms due to gluten exposure, in participants with celiac disease (CeD) attempting to maintain a gluten-free diet (GFD) in treated participants versus placebo controls.
The 2 groups in the trial
- Placebo + SIGE Gluten capsulePlacebo, for comparison
Placebo subcutaneous (SC) injection as per protocol + SIGE Gluten capsule orally
Treatment: Placebo DONQ52 and Simulated Inadvertent Gluten Exposure (SIGE) capsule
- DONQ52 + SIGE Gluten capsuleTreatment being tested
DONQ52 subcutaneous (SC) injection as per protocol + SIGE Gluten capsule orally
Treatment: DONQ52 and Simulated Inadvertent Gluten Exposure (SIGE) capsule
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase II, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate The Efficacy and Safety of DONQ52 in Active Celiac Disease Patients Who Have Duodenal Mucosal Damage and Persistent Symptoms Despite Attempting A Gluten-free Diet (DAISY STUDY)
- Plain-language title
- DONQ52 for Celiac Disease With Ongoing Symptoms Despite a Gluten-Free DietGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Criteria questions
- Built from NCT07239336, who can take part
- Record updated
- 14 August 2026